Factor V Leiden: A Review of the Literature

Journal of Perinatal and Neonatal Nursing

Volumn 17, Issue 3, 2003, Pages 190-195

  Ament, Lynette ^a  

^a YALE UNIVERSITY SCHOOL OF NURSING   (United States)

Author keywords

Factor V Leiden; Fetal growth restriction; Preeclampsia; Pregnancy; Pregnancy loss; Venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN;

FEMALE; GENETICS; HUMAN; INTRAUTERINE GROWTH RETARDATION; NURSING; NURSING METHODOLOGY RESEARCH; POINT MUTATION; PREGNANCY; PREGNANCY COMPLICATION; RECURRENT ABORTION; REVIEW; RISK FACTOR; THROMBOEMBOLISM; VEIN THROMBOSIS;

ABORTION, HABITUAL; FACTOR V; FEMALE; FETAL GROWTH RETARDATION; HUMANS; NURSING METHODOLOGY RESEARCH; POINT MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0141652876     PISSN: 08932190     EISSN: 15505073     Source Type: Journal    
DOI: 10.1097/00005237-200307000-00004     Document Type: Article

References (38)

1. Spina V, Aleandri V, Morini F. The impact of the factor V Leiden mutation on pregnancy. Hum Reprod Update. 2000;6:301-306.
2. Middeldorp S, Meinardi Johan R, Koopman Maria MW, et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med. 2001;135:322-327.
3. Livingston Jeffrey C, Barton John R, Park V, Haddad B, Phillips O, Sibai Baha M. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am J Obstet Gynecol. 2001;185:153-157.
4. Bertina MR, Koelman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
5. Miles AM, Mongra M. Factor V Leiden mutation: the most commonly inherited risk factor for venous thrombosis. Prim Care Update OB/GYN. 1996;6:141-146.
6. Zoller B, Svensson PJ, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis prone families with inherited resistance to activated protein C. J Clin Invest. 1994;94:2521-2524.
7. Dahlback B. Resistance to activated protein C, the Arg 506 to Gln mutation in the factor V gene, and venous thrombosis. Thromb Hemost. 1995;73:739-742.
8. Creinin Mitchell D, Lisman R, Strickler Ronald C. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Am Soc Reprod Med. 1999;72:646-651.
9. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. J Am Med Assoc. 1997;277:1305-1307.
10. Lockwood CJ. Heritable coagulopathies in pregnancy. Obstet Gynecol Surv. 1999;54:754-765.
11. Bonnar J, Green R, Norris L. Perinatal aspects of inherited thrombophilia. Semin Thromb Hemost. 1999;25;481-485.
12. Thromboembolism in pregnancy. ACOG Pract Bull. 2000;19.
13. Lindqvist P, Olofsson P, Dahlback B. Use of selective factor V Leiden screening in pregnancy to identify candidates for anticoagulants. Am Coll Obstet Gynecol. 2002;100:332-336.
14. Clark P, Twaddle S, Walker ID, Scott L, Greer IA. Cost-effectiveness of screening for factor V Leiden mutation in pregnant women. Lancet. 2002;359:1919-1920.
15. Tormene D, Simioni P, Prandoni P, et al. Factor V Leiden mutation and the risk of venous thromboembolism in pregnant women. Haematologica. 2001;86:1306-1309.
16. Alfirevic Z, Mousa HA, Martlew V, Briscoe L, Perez-Casal M, Toh CH. Postnatal screening for thrombophilia in women with severe pregnancy complications. Obstet Gynecol. 2001;97:753-759.
17. Pabinger I, Nemes L, Rintelen C, et al. Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden. Hematol J. 2000;1:37-41.
18. Dizon-Townson D. Pregnancy-related venous thromboembolism. Clin Obstet Gynecol. 2002;45:363-368.
19. van Pampus Maria G, Dekker Gustaf A, Wolf H, et al. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol. 1999;180:1146-1150.
20. Lindoff C, Ingermarsson I, Martinsson G, Segemark M, Thysell H, Asedt B. Preeclampsia is associated with a reduced response to activated protein C. Am J Obstet Gynecol. 1997;175:457-469.
21. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden, C > T MTHFR polymorphism and genetic susceptibility to preeclampsia. Thromb Hemost. 1997;77:1052-1054.
22. Hastins S, Knowlton J, Nelson L, et al. Obstetrical and medical complications in women with the factor V Leiden mutation. Am J Obstet Gynecol. 1998;178:S104.
23. Rigo J, Nagy B, Fintor L, et al. Maternal and neonatal outcome of preeclamptic pregnancies: the potential roles of factor V Leiden mutation and 5,10 methylenetetradydrofolate reductase. Hypert Preg. 2000;19:163-172.
24. Kim Young J, Williamson Roger A, Murray Jeffrey C, et al. Genetic susceptibility to preeclampsia: roles of cytosineto-thymine substitution at nucleotide 677 of the gene for methylenetetrahydrofolate reductase, 68-base pair insertion at nucleotide 844 of the gene for cystathionine (beta)-synthase, and factor V Leiden mutation. Am J Obstet Gynecol. 2001;184:1211-1217.
25. DeGroot Christine JM, Bloemenkamp Kitty WM, Duvekot Ella J, et al. Preeclampsia and genetic risk factors for thrombosis: a case-control study. Am J Obstet Gynecol. 1999;181:975-980.
26. Krauss T, Augustin HG, Osmers R, et al. Activated protein C resistance and factor V Leiden in patients with hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol. 1998;92:457-460.
27. Bozzo M, Carpani G, Leo L, et al. HELLP syndrome and factor V Leiden. Eur J Obstet Gynecol Reprod Biol. 2001;95:55-58.
28. Rigo J Jr, Nagy B, Fintor L. Factor V leiden mutation and preeclampsia. Am J Obstet Gynecol. 2002;186:853.
29. Meinardi Johan R, Middeldorp S, de Kam Pieter J, et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med. 1999;130:736-739.
30. Brenner B, Mandel H, Lamir N, et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol. 1997;97:551-554.
31. Grandone E, Margaglione M, Colaizzo D, et al. Lower birth-weight in neonates of mothers carrying factor V G1691A and factor llA (20210) mutations. Haematologica. 2002;87:177-181.
32. Balasch J, Reverter JC, Fabregues F, et al. First-trimester repeated abortion is not associated with activated protein C resistance. Hum Reprod. 1997;12:1094-1097.
33. Wramsby ML, Sten-Linder M, Bremme K. Primary habitual abortions are associated with high frequency of factor V Leiden mutation. Fertil Steril. 2000;74:987-991.
34. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet. 1995;346:1582-1588.
35. Jick H, Jick SS, Gurewich V, Myers MW, Vasiladis C. Risk of idiopathic death and non-fatal thromboembolism in women using oral contraceptives with different progestogen components. Lancet. 1995;346:1588-1593.
36. Herrington D, Vittinghoff E, Howard T, et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol. 2002;22:1012-1017.
37. Bloomenthal D, vonDadelszen P, Liston R, Magee L, Tsang P. The effect of factor V Leiden carriage on maternal and fetal health. CMAJ. 2002;167:48-54.
38. Greer A. The acute management of venous thromboembolism in pregnancy. Curr Opin Obstet Gynecol. 2001;13:569-575.